Tsegaye, Arega
Demissew, Assalif
Hawaria, Dawit
Getachew, Hallelujah
Habtamu, Kassahun
Asale, Abebe
Yan, Guiyun
Yewhalaw, Delenasaw
Article History
Received: 7 May 2022
Accepted: 22 August 2022
First Online: 21 October 2022
Declarations
:
: The protocol was reviewed and approved by National Research Ethics Review committee (NRERC) of the Ethiopia (Ref. no.: 10/31/2018). Permission was also obtained from the Buno Bedele and East Wollega Zonal Health Offices, and from the Arjo-Didessa Sugar factory, Oromia Regional State, Ethiopia. Gametocyte carriers were recruited among febrile patients visiting selected health facilities to seek treatment for malaria. Gametocytemic study participants with <i>P. vivax</i> and <i>P. falciparum</i> infection were informed of the risks and the benefits of the study. Consent was obtained from participants or legal guardians/parents in the case of children. Throughout the study, all malaria-positive patients, as determined by microscopic examination of blood film, were treated as per the national malaria treatment guideline for free.
: Not applicable.
: The authors declare no competing interests.